Nothing Special   »   [go: up one dir, main page]

Sauerwein et al., 2021 - Google Patents

Theranostics in boron neutron capture therapy

Sauerwein et al., 2021

View HTML
Document ID
6303002226471999518
Author
Sauerwein W
Sancey L
Hey-Hawkins E
Kellert M
Panza L
Imperio D
Balcerzyk M
Rizzo G
Scalco E
Herrmann K
Mauri P
De Palma A
Wittig A
Publication year
Publication venue
Life

External Links

Snippet

Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493Steroids, e.g. cholesterol, testosterone
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Similar Documents

Publication Publication Date Title
Sauerwein et al. Theranostics in boron neutron capture therapy
Hennrich et al. [68Ga] Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer
Ballal et al. First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu] Lu-DOTA. SA. FAPi and [177Lu] Lu-DOTAGA.(SA. FAPi) 2
Vahidfar et al. Theranostic advances in breast cancer in nuclear medicine
Awenat et al. Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review
Hirata et al. The Roles of hypoxia imaging using 18F-fluoromisonidazole positron emission tomography in glioma treatment
Fortuin et al. Molecular and functional imaging for detection of lymph node metastases in prostate cancer
Plichta et al. Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer
Vorobyeva et al. Indirect radioiodination of DARPin G3 using N-succinimidyl-para-iodobenzoate improves the contrast of HER2 molecular imaging
Hu et al. Radiosynthesis and preclinical evaluation of bispecific PSMA/FAP heterodimers for tumor imaging
Wong et al. 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a Phase I trial
Patterson et al. Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry
Abouzayed et al. Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS/SES-PEG2-RM26 for imaging of prostate cancer
Bragina et al. Direct intra-patient comparison of scaffold protein-based tracers,[99mTc] Tc-ADAPT6 and [99mTc] Tc-(HE) 3-G3, for imaging of HER2-Positive breast cancer
Lundmark et al. Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation
Herrmann et al. Molecular imaging of tumors using a quantitative T 1 mapping technique via magnetic resonance imaging
Marenco et al. Chemical and physical characterisation of human serum albumin nanocolloids: kinetics, strength and specificity of bonds with 99mTc and 68Ga
Liu et al. Experimental therapy of HER2-expressing xenografts using the second-generation HER2-targeting affibody molecule 188Re-ZHER2: 41071
Brighi et al. Comparison between [68Ga] Ga-PSMA-617 and [18F] FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma
Liu et al. Recent advances in imaging agents anchored with pH (Low) insertion peptides for cancer theranostics
Csikos et al. In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn] Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
Ren et al. An albumin-binding PSMA ligand with higher tumor accumulation for PET imaging of prostate cancer
Ferrari et al. [18F] fluciclovine vs.[18F] fluorocholine positron emission tomography/computed tomography: a head-to-head comparison for early detection of biochemical recurrence in prostate cancer patients
Luo et al. SPECT imaging with Tc-99m-labeled HYNIC-FAPI-04 to extend the differential time window in evaluating tumor fibrosis
Davis et al. Personalisation of molecular radiotherapy through optimisation of theragnostics